Evidence supporting the use of anti-CD20 as first-line steroid-sparing agent in childhood nephrotic syndrome.

IF 12.6 1区医学 Q1 UROLOGY & NEPHROLOGY

Kidney international Pub Date : 2025-06-10 DOI:10.1016/j.kint.2025.04.009

Claire Dossier, Julien Hogan

引用次数: 0

查看原文本刊更多论文

支持使用抗cd20作为一线类固醇保留剂治疗儿童肾病综合征的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Kidney international 医学-泌尿学与肾脏学

CiteScore

23.30

自引率

3.10%

发文量

490

审稿时长

3-6 weeks

期刊介绍： Kidney International (KI), the official journal of the International Society of Nephrology, is led by Dr. Pierre Ronco (Paris, France) and stands as one of nephrology's most cited and esteemed publications worldwide. KI provides exceptional benefits for both readers and authors, featuring highly cited original articles, focused reviews, cutting-edge imaging techniques, and lively discussions on controversial topics. The journal is dedicated to kidney research, serving researchers, clinical investigators, and practicing nephrologists.